Revelation Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.75
- Today's High:
- $0.8099
- Open Price:
- $0.7819
- 52W Low:
- $0.667
- 52W High:
- $17.549
- Prev. Close:
- $0.798
- Volume:
- 27143
Company Statistics
- Market Cap.:
- $5.03 million
- Book Value:
- 1.813
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $90.91 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -36.96%
- Return on Equity TTM:
- 48.74%
Company Profile
Revelation Biosciences Inc had its IPO on 2020-11-17 under the ticker symbol REVB.
The company operates in the Healthcare sector and Biotechnology industry. Revelation Biosciences Inc has a staff strength of 6 employees.
Stock update
Shares of Revelation Biosciences Inc opened at $0.78 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.75 - $0.81, and closed at $0.77.
This is a -3.5% slip from the previous day's closing price.
A total volume of 27,143 shares were traded at the close of the day’s session.
In the last one week, shares of Revelation Biosciences Inc have increased by +14.09%.
Revelation Biosciences Inc's Key Ratios
Revelation Biosciences Inc has a market cap of $5.03 million, indicating a price to book ratio of 0.8909 and a price to sales ratio of 2.8821.
In the last 12-months Revelation Biosciences Inc’s revenue was $0 with a gross profit of $90.91 million and an EBITDA of $-5945619. The EBITDA ratio measures Revelation Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Revelation Biosciences Inc’s operating margin was 0% while its return on assets stood at -36.96% with a return of equity of 48.74%.
In Q2, Revelation Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Revelation Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 7.7942
- Trailing PE
- 0.7321
- PEG
Its diluted EPS in the last 12-months stands at $1.09 per share while it has a forward price to earnings multiple of 7.7942 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Revelation Biosciences Inc’s profitability.
Revelation Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 2.8821.
Revelation Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $16.04 million
- Total Liabilities
- $4.62 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Revelation Biosciences Inc ended 2024 with $16.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $16.04 million while shareholder equity stood at $11.41 million.
Revelation Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $4.62 million in other current liabilities, 6297.00 in common stock, $-20635823.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.71 million and cash and short-term investments were $15.71 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Revelation Biosciences Inc’s total current assets stands at $15.96 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $913866.00 and inventory worth $0.
In 2024, Revelation Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Revelation Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.77
- 52-Week High
- $17.549
- 52-Week Low
- $0.667
- Analyst Target Price
- $11.45
Revelation Biosciences Inc stock is currently trading at $0.77 per share. It touched a 52-week high of $17.549 and a 52-week low of $17.549. Analysts tracking the stock have a 12-month average target price of $11.45.
Its 50-day moving average was $0.78 and 200-day moving average was $2.93 The short ratio stood at 0.1 indicating a short percent outstanding of 0%.
Around 683% of the company’s stock are held by insiders while 1367.6% are held by institutions.
Frequently Asked Questions About Revelation Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.